Biomedical Diagnostics (BMD) appoints Michel Finance as CEO
Biomedical Diagnostics (BMD) announced the appointment of Michel Finance as its CEO.
Philippe Pouletty MD, BMD Chairman and Managing Partner at Truffle Capital, BMD's majority shareholder, had occupied the position of interim CEO for the previous year and had successfully transitioned the company towards a healthy financial and operational situation. Michel Finance's arrival at Biomedical Diagnostics forms part of the company’s initiative to strengthen its management structure and base its development on innovation - notably in the field of inflammatory disease.
Michel Finance
Michel Finance joins Biomedical Diagnostics after 25 years in senior management in the pharmaceutical and biotechnology sectors. Prior to joining Biomedical Diagnostics, Michel Finance was Deputy CEO at Neovacs, a company developing therapeutic vaccines against auto-immune diseases, where he successfully led the company’s IPO on Alternext in April 2010. Between 2010 and 2002, Michel Finance was CEO at Carmat, a medtech company developing the world's most advanced total artificial heart listed on Alternext in July 2010, was Executive VP at Flamel Technologies, the NASDAQ-listed drug delivery specialist, and Corporate Controller and Senior Vice President at the Aventis Group.
Prior to this, Michel Finance had served in various operational positions at the Aventis Group in France, Germany and Canada. Michel Finance is also a Board Member at Carmat, Neovacs and France Biotech, the French life science industry association. Michel Finance is 53 years old and is a graduate of the Lyons Business School (class of 1980). He has dual French and Canadian citizenship and is a Knight of the French National Order of Merit.
Other news from the department people
